Nektar Historical Income Statement
NKTR Stock | USD 1.46 0.14 10.61% |
Historical analysis of Nektar Therapeutics income statement accounts such as Gross Profit of 50.8 M can show how well Nektar Therapeutics performed in making a profits. Evaluating Nektar Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Nektar Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Nektar Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Nektar Therapeutics is a good buy for the upcoming year.
Nektar |
About Nektar Income Statement Analysis
Nektar Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Nektar Therapeutics shareholders. The income statement also shows Nektar investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Nektar Therapeutics Income Statement Chart
Nektar Therapeutics Income Statement is one of the three primary financial statements used for reporting Nektar's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Nektar Therapeutics revenue and expense. Nektar Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Nektar Therapeutics' Total Revenue is relatively stable compared to the past year. As of 05/01/2024, Other Operating Expenses is likely to grow to about 258 M, while Interest Expense is likely to drop slightly above 23.9 M. Add Fundamental
Total Revenue
Total revenue comprises all receipts Nektar Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Nektar Therapeutics minus its cost of goods sold. It is profit before Nektar Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Nektar Therapeutics. It is also known as Nektar Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Nektar Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Nektar Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.At this time, Nektar Therapeutics' Total Revenue is relatively stable compared to the past year. As of 05/01/2024, Other Operating Expenses is likely to grow to about 258 M, while Interest Expense is likely to drop slightly above 23.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 77.0M | 70.4M | 53.5M | 50.8M | Total Revenue | 101.9M | 92.1M | 90.1M | 162.3M |
Nektar Therapeutics income statement Correlations
Click cells to compare fundamentals
Nektar Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Nektar Therapeutics income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 59.5M | 32.5M | (7.7M) | 19.7M | 7.8M | 7.4M | |
Interest Expense | 46.4M | 37.1M | 47.3M | 28.9M | 25.3M | 23.9M | |
Total Revenue | 114.6M | 152.9M | 101.9M | 92.1M | 90.1M | 162.3M | |
Gross Profit | 93.2M | 133.4M | 77.0M | 70.4M | 53.5M | 50.8M | |
Other Operating Expenses | 554.7M | 532.8M | 548.0M | 332.3M | 227.5M | 258.0M | |
Operating Income | (440.0M) | (379.9M) | (446.1M) | (240.2M) | (137.4M) | (144.3M) | |
Ebit | (440.0M) | (379.9M) | (446.1M) | (240.2M) | (137.4M) | (130.6M) | |
Ebitda | (380.5M) | (347.5M) | (453.8M) | (220.5M) | (129.6M) | (123.1M) | |
Cost Of Revenue | 21.4M | 19.5M | 24.9M | 21.6M | 36.6M | 26.8M | |
Total Operating Expenses | 533.3M | 513.4M | 523.1M | 310.7M | 190.9M | 228.8M | |
Income Before Tax | (440.1M) | (443.9M) | (523.3M) | (365.0M) | (276.3M) | (262.4M) | |
Total Other Income Expense Net | (19K) | (64.0M) | (77.2M) | (124.7M) | (138.8M) | (131.9M) | |
Net Income | (440.7M) | (444.4M) | (523.8M) | (368.2M) | (276.1M) | (262.3M) | |
Income Tax Expense | 613K | 493K | 557K | 3.2M | (200K) | (190K) | |
Research Development | 434.6M | 408.7M | 400.3M | 218.3M | 111.3M | 184.5M | |
Selling General Administrative | 98.7M | 104.7M | 122.8M | 92.3M | 77.4M | 52.5M | |
Net Income From Continuing Ops | (440.7M) | (444.4M) | (523.8M) | (368.2M) | (293.7M) | (279.0M) | |
Non Operating Income Net Other | 37.6M | 46.3M | 18.3M | (29.9M) | (34.3M) | (32.6M) | |
Net Income Applicable To Common Shares | (440.7M) | (444.4M) | (523.8M) | (368.2M) | (331.4M) | (314.8M) | |
Tax Provision | 613K | 493K | 557K | 3.2M | 3.0M | 3.1M | |
Interest Income | 46.3M | 18.3M | 2.6M | 6.7M | 17.6M | 15.4M | |
Net Interest Income | (19K) | (18.8M) | (44.7M) | (22.2M) | (8.1M) | (8.5M) | |
Reconciled Depreciation | 13.2M | 14.2M | 14.1M | 13.0M | 9.3M | 10.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Nektar Stock analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Nektar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nektar Therapeutics. If investors know Nektar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nektar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.45) | Revenue Per Share 0.474 | Quarterly Revenue Growth 0.085 | Return On Assets (0.15) | Return On Equity (1.11) |
The market value of Nektar Therapeutics is measured differently than its book value, which is the value of Nektar that is recorded on the company's balance sheet. Investors also form their own opinion of Nektar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nektar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nektar Therapeutics' market value can be influenced by many factors that don't directly affect Nektar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nektar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nektar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nektar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.